Alexion

Jazz Pharma, Lundbeck and Alexion Pay $122 Million to Settle Kickback Allegations
BioSpace
Thu, 04/4/19 - 11:02 pm
Jazz Pharma
Lundbeck
Alexion
kickbacks
charity
Alexion chief registers $16.5M in pay after a solid year, with a relatively low 74-to-1 ratio compared to a well paid staff
Endpoints
Tue, 03/26/19 - 10:15 am
Alexion
Pharma CEOs
executive pay
Ludwig Hantson
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Wed, 03/6/19 - 09:59 am
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Alexion runs toward big Ultomiris goals with early Soliris switching success
Fierce Pharma
Tue, 02/5/19 - 11:17 pm
Alexion
Ultomiris
paroxysmal nocturnal hemoglobinuria
PNH
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
Forbes
Mon, 01/28/19 - 11:00 am
Big Pharma
Pfizer
Merck
AstraZeneca
Gilead Sciences
Alexion
Vertex Pharmaceuticals
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
Fri, 01/11/19 - 10:25 am
JPMHC 2019
Merck
FDA
M&A
Celgene
Bristol-Myers Squibb
Genevant
IPOs
Eli Lilly
Novartis
GSK
Teva Pharmaceutical
Alexion
Pear Therapeutics
FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria
GoinPharma
Fri, 12/28/18 - 01:00 pm
Alexion
FDA
ALXN1210
Ultomiris
PNH
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
Mon, 12/10/18 - 09:50 am
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Alexion to buy biotech firm Syntimmune for up to $1.2 billion
Reuters
Wed, 09/26/18 - 07:24 pm
Alexion
Syntimmune
M&A
Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Endpoints
Mon, 09/24/18 - 03:33 pm
Alexion
Soliris
clinical trials
NMOSD
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
CP Wire
Mon, 08/20/18 - 11:40 am
Alexion Pharmaceuticals
Alexion
FDA
ALXN210
PNH
paroxysmal nocturnal hemoglobinuria
Vertex and Alexion Are Schooling Big Biotech
Washington Post, DC
Fri, 07/27/18 - 11:19 pm
earnings
Vertex Pharmaceuticals
Alexion
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Fierce Pharma
Mon, 07/16/18 - 10:34 pm
Amgen
biosimilars
Neulasta
Alexion
M&A
How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass
Biopharma Dive
Tue, 06/19/18 - 09:40 pm
Alexion
Soliris
fast pass
FDA
priority review
ALXN1210
Big Biotech Set for Earnings Blowout?
Barron's
Sat, 06/16/18 - 01:24 pm
biotech
earnings
Gilead Sciences
Alexion
Vertex Pharmaceuticals
Alexion snags option to buy neurodegeneration startup Complement
Fierce Biotech
Mon, 06/11/18 - 10:01 pm
Alexion
Complement Pharma
M&A
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
Endpoints
Tue, 05/29/18 - 09:22 pm
M&A
JNJ
Merck
Pfizer
Gilead Sciences
Amgen
Biogen
Takeda
Regeneron
Alexion
Biopharma M&A: You Ain’t Seen Nothing Yet
Barron's
Fri, 05/25/18 - 09:32 am
JNJ
Merck
Pfizer
Gilead Sciences
Amgen
Regeneron
Alexion
M&A
Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline
Stat
Wed, 04/11/18 - 11:10 am
Alexion
WIlson Therapeutics
M&A
Rare Diseases
When Will They Learn? 4 Huge Biotech Blowups
Motley Fool
Thu, 03/29/18 - 09:24 pm
biotech
AstraZeneca
ZS-9
drug manufacturing
Alexion
Synageva
Merck
Cubist Pharmaceuticals
AbbVie
Rova-T
Stemcentrx

Pages